Publications
142 results found
Tassone D, Hartley I, Ding NS, 2023, Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol: 58, Pages: 729-730, ISSN: 0269-2813
Tassone D, Hartley I, Ding NS, 2023, Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol: 58, Pages: 376-377, ISSN: 0269-2813
Noor NM, Sousa P, Bettenworth D, et al., 2023, ECCO Topical Review on Biological Treatment Cycles in Crohn's Disease, JOURNAL OF CROHNS & COLITIS, Vol: 17, Pages: 1031-1045, ISSN: 1873-9946
Hartley I, Lee T, Ding NS, 2023, Editorial: improving the use of Montreal classification through a bidirectional approach, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol: 58, Pages: 112-113, ISSN: 0269-2813
Yu N, Sriranganathan D, Walker GJ, et al., 2023, Prevalence of NUDT15 Genetic Variants and Incidence of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis, JOURNAL OF CROHNS & COLITIS, ISSN: 1873-9946
Tassone D, Gilmore R, Lee T, et al., 2023, Letter: diagnostic delay in inflammatory bowel disease, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol: 57, Pages: 1203-1204, ISSN: 0269-2813
- Author Web Link
- Cite
- Citations: 1
Gilmore R, Tassone D, Ding NS, 2023, Letter: tofacitinib in the real world - do clinical trial data stand up?, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol: 57, Pages: 745-746, ISSN: 0269-2813
Misra R, Sarafian M, Pechlivanis A, et al., 2022, Ethnicity associated microbial and metabonomic profiling in newly diagnosed ulcerative colitis, Clinical and Experimental Gastroenterology, Vol: 15, Pages: 199-212, ISSN: 1178-7023
Introduction:Ulcerative colitis (UC) differs across geography and ethnic groups. Gut microbial diversity plays a pivotal role in disease pathogenesis and differs across ethnic groups. The functional diversity in microbial-driven metabolites may have a pathophysiologic role and offer new therapeutic avenues.Methods:Demographics and clinical data were recorded from newly diagnosed UC patients. Blood, urine and faecal samples were collected at three time points over one year. Bacterial content was analysed by 16S rRNA sequencing. Bile acid profiles and polar molecules in three biofluids were measured using liquid-chromatography mass spectrometry (HILIC) and nuclear magnetic resonance spectroscopy.Results:We studied 42 patients with a new diagnosis of UC (27 South Asians; 15 Caucasians) with 261 biosamples. There were significant differences in relative abundance of bacteria at the phylum, genus and species level. Relative concentrations of urinary metabolites in South Asians were significantly lower for hippurate (positive correlation for Ruminococcus) and 4-cresol sulfate (Clostridia) (p<0.001) with higher concentrations of lactate (negative correlation for Bifidobacteriaceae). Faecal conjugated and primary conjugated bile acids concentrations were significantly higher in South Asians (p=0.02 and p=0.03 respectively). Results were unaffected by diet, phenotype, disease severity and ongoing therapy. Comparison of time points at diagnosis and at 1 year did not reveal changes in microbial and metabolic profile.Conclusion:Ethnic-related microbial metabolite associations were observed in South Asians with UC. This suggests a predisposition to UC may be influenced by environmental factors reflected in a distinct gene-environment interaction. The variations may serve as markers to identify risk factors for UC and modified to enhance therapeutic response.
Louis E, Resche-Rigon M, Laharie D, et al., 2022, TREATMENT DE-ESCALATION IN CROHN'S DISEASE PATIENTS IN REMISSION UNDER INFLIXIMAB AND IMMUNOSUPPRESSANT THERAPY: THE SPARE TRIAL, Annual Meeting of the British-Society-of-Gastroenterology (BSG), Publisher: BMJ PUBLISHING GROUP, Pages: A27-A27, ISSN: 0017-5749
- Author Web Link
- Cite
- Citations: 2
Ding NS, Tassone D, Al Bakir I, et al., 2022, Systematic review: the impact and importance of body composition in inflammatory bowel disease, Journal of Crohns & Colitis, ISSN: 1873-9946
Background and AimsAlterations in body composition are common in inflammatory bowel disease [IBD] and have been associated with differences in patient outcomes. We sought to consolidate knowledge on the impact and importance of body composition in IBD.MethodsWe performed a systematic search of MEDLINE, EMBASE and conference proceedings by combining two key research themes: inflammatory bowel disease and body composition.ResultsFifty-five studies were included in this review. Thirty-one focused on the impact of IBD on body composition with a total of 2279 patients with a mean age 38.4 years. Of these, 1071 [47%] were male. In total, 1470 [64.5%] patients had Crohn’s disease and 809 [35.5%] had ulcerative colitis. Notably, fat mass and fat-free mass were reduced, and higher rates of sarcopaenia were observed in those with active IBD compared with those in clinical remission and healthy controls. Twenty-four additional studies focused on the impact of derangements in body composition on IBD outcomes. Alterations in body composition in IBD are associated with poorer prognoses including higher rates of surgical intervention, post-operative complications and reduced muscle strength. In addition, higher rates of early treatment failure and primary non-response are seen in patients with myopaenia.ConclusionsPatients with IBD have alterations in body composition parameters in active disease and clinical remission. The impacts of body composition on disease outcome and therapy are broad and require further investigation. The augmentation of body composition parameters in the clinical setting has the potential to improve IBD outcomes in the future.
Ding NS, Lee T, Bettenworth D, et al., 2021, Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, Vol: 33, Pages: E837-E842, ISSN: 0954-691X
Adegbola SO, Sarafian M, Sahnan K, et al., 2021, Differences in amino acid and lipid metabolism distinguish Crohn's from idiopathic/cryptoglandular perianal fistulas by tissue metabonomic profiling and may offer clues to underlying pathogenesis, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, Vol: 33, Pages: 1469-1479, ISSN: 0954-691X
Mattoo VY, Basnayake C, Connell WR, et al., 2021, Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol: 54, Pages: 249-266, ISSN: 0269-2813
- Author Web Link
- Cite
- Citations: 5
Tassone D, Singh S, Sheng Ding N, 2021, Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol: 54, Pages: 206-207, ISSN: 0269-2813
Tambakis G, Lee T, Shah R, et al., 2021, Low failure to attend rates and increased clinic capacity with Telehealth: A highly effective outpatient model that should continue beyond the COVID-19 pandemic, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol: 36, Pages: 1136-1137, ISSN: 0815-9319
- Author Web Link
- Cite
- Citations: 1
Lee T, Kamm MA, Bell S, et al., 2021, Long-term outcomes of perianal fistulizing Crohn's disease in the biologic era, JGH OPEN, Vol: 5, Pages: 235-241, ISSN: 2397-9070
- Author Web Link
- Cite
- Citations: 1
Gu B, De Gregorio M, Pipicella JL, et al., 2021, Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol, BMJ OPEN, Vol: 11, ISSN: 2044-6055
- Author Web Link
- Cite
- Citations: 3
Mattoo V, Basnayake C, Connell W, et al., 2020, Escalated anti-tumor necrosis factor agent dosing in inflammatory bowel disease is associated with higher drug levels and a reduction in fecal calprotectin level for infliximab but not adalimumab, Publisher: WILEY, Pages: 140-140, ISSN: 0815-9319
De Gregorio M, Lee T, Krishnaprasad K, et al., 2020, Higher anti-tumor necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulizing Crohn's disease: A retrospective multicenter study, Publisher: WILEY, Pages: 133-133, ISSN: 0815-9319
Dragoni G, Ding N, Gecse KB, et al., 2020, The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, Vol: 32, Pages: 1062-1066, ISSN: 0954-691X
- Author Web Link
- Cite
- Citations: 7
Chan W, Kariyawasam VC, Kim S, et al., 2020, Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, Vol: 32, Pages: 976-983, ISSN: 0954-691X
- Author Web Link
- Cite
- Citations: 8
Ding NS, McDonald JAK, Perdones-Montero A, et al., 2020, Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease, JOURNAL OF CROHNS & COLITIS, Vol: 14, Pages: 1090-1102, ISSN: 1873-9946
- Author Web Link
- Cite
- Citations: 51
Cordes F, Foell D, Ding JN, et al., 2020, Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease, WORLD JOURNAL OF GASTROENTEROLOGY, Vol: 26, Pages: 4055-4075, ISSN: 1007-9327
- Author Web Link
- Cite
- Citations: 36
Ding NS, An P, Dong W, et al., 2020, reply, LANCET GASTROENTEROLOGY & HEPATOLOGY, Vol: 5, Pages: 640-641
An P, Ji M, Ren H, et al., 2020, Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China, LANCET GASTROENTEROLOGY & HEPATOLOGY, Vol: 5, Pages: 525-527
- Author Web Link
- Cite
- Citations: 68
Lee T, Yong E, Ding NS, 2020, Radiological outcomes in perianal fistulizing Crohn's disease: A systematic review and meta-analysis, JGH OPEN, Vol: 4, Pages: 340-344, ISSN: 2397-9070
- Author Web Link
- Cite
- Citations: 14
Adegbola S, Sarafian M, Sahnan K, et al., 2020, MetabonomicProfiling Distinguishes Crohn's Perianal Fistulas and Idiopathic Idiopathic (Cryptoglandular) Perianal Fistulas - Possible Clues to Underlying Pathogenesis?, International Surgical Conference of the Association-of-Surgeons-in-Training, Publisher: WILEY, Pages: 17-17, ISSN: 0007-1323
Hui S, Krishna A, Ding NS, et al., 2020, Vedolizumab for induction and maintenance of remission in Crohn’s disease, Cochrane Database of Systematic Reviews, Vol: 2020
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. The primary objective of this systematic review of the literature is to assess the efficacy and safety of vedolizumab in the induction and maintenance of remission in Crohn's disease.
Lee T, Gilbert L, van Langenberg DR, et al., 2020, HIGHER ANTI-TNFα TROUGH LEVELS ARE ASSOCIATED WITH INCREASED RADIOLOGICAL RESPONSE IN PERIANAL FISTULISING CROHN'S DISEASE: A MULTI-CENTRE STUDY, Crohn's and Colitis Congress, Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S1038-S1038, ISSN: 0016-5085
Wann S, Norris R, Williams R, et al., 2020, Endoscopic and histological activity is associated with non-response to biologic therapy in ulcerative colitis, Publisher: OXFORD UNIV PRESS, Pages: S376-S376, ISSN: 1873-9946
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.